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Background:  Approximately 5.3 million Americans, aged 18 and over, carry a diagnosis of 
diabetic retinopathy (DR).  By the year 2050 this number is expected to triple without effective 
healthcare intervention.  Approximately 4.8% of the global blindness is attributable to DR, a 
silent, progressive, microvascular complication of diabetes.  Best practice dictates immediate 
screening at time of diagnosis of Type II Diabetes Mellitus (T2DM) and biennial screenings 
thereafter, yet this need is often unmet.   
Purpose:  This study is a continuation of a process put into place by Dr. Michelle Campbell in 
October 2017 at the Norton Community Medical Associates Mount Washington practice and was 
to determine effectiveness of this intervention.  This intervention involved formal referral with a 
specific form documenting the results of the ophthalmological screening being faxed back to the 
primary care office and scanned into the patient’s electronic health record (EHR).   
Methods:  This study used a retrospective chart review for the period 1 January 2017 to 1 May 
2017 and 1 January 2018 to 1 May 2018 to determine the number of formal referrals to 
ophthalmology pre- and post-implementation as well as the number of formal documentation 
forms received during both time periods.    Inclusion criteria included T2DM, ICD-10 codes 
E11.0-E11.9, and ages between 18 years and 70 years. One hundred charts were selected by the 
Information Technology Department for both pre- and post-implementation review.  
Results:  SPSS Software was used to analyze the data.  A chi square test was used to measure 
these results.  Pre- and post-implementation referrals yielded a p-value of 0.321 which was not 
statistically significant; however,  pre- and post-implementation documentation yielded a p-value 
of .016 which was significant, unfortunately in the opposite direction than was hoped.   





 DR is the most prevalent cause of blindness world-wide.  Interestingly, if found early 
enough, there are treatments available to prevent blindness.  However, this needed screening is 
often not obtained in the T2DM population, whether due to the challenge of going to different 
facilities for appointments, the lack of knowledge that this is a serious, microvascular 
complication of diabetes that is often painless and asymptomatic until too late, or because the 
patient just has too much other information to digest and control.  Unfortunately, the reasoning 
remains unclear as to why screenings are not more consistent in this population.  The purpose of 
this project was to review  the rates of referral for retinopathy screening prior to the 
implementation of a formal referral and a formal documentation process to capture these 
important screenings in patient’s electronic medical records. 
Background 
In the United States, there are approximately 5.3 million persons, aged 18 and over, with 
a diagnosis of DR (CDC, 2015).  This disease is caused by elevated blood glucose levels which 
cause damage to the tiny blood vessels in the retina of the eye (Weiss et al., 2015).  DR is 
specifically a microvascular complication of diabetes that is  exacerbated by hypertension in the 
uncontrolled diabetic (Molinaro and Dauscher, 2017).  By the year 2050 it is anticipated that this 
number will triple (Zangalli et al., 2016) without effective healthcare intervention.  Global health 
spending in 2015 to treat and prevent T2DM complications were somewhere between $673 
billion and $1.2 billion (Adil, Siddiqui, Waghdhare, Bhargava & Jha, 2017).   Comparatively, in 
2004 alone, more than $500 million was spent on healthcare costs, both direct and indirect, 
related to blindness and complications caused by DR  (Weiss et al., 2015); an increase of 
approximately $173 million in eleven years-time.  Americans aged 20 to 74 with a new-onset of 
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blindness (Weiss et al, 2015) due to DR is expected to create a substantial and costly burden to 
healthcare (Zangalli et al, 2016).  Interestingly, DR screening and treatment are reportedly highly 
cost-effective from a healthcare payer and societal view (Kreft, McGuinness, Doblhammer, & 
Finger, 2018). 
Diabetic patients have increased risk for visual loss related to cataracts and glaucoma, 
retinopathy and correctable visual impairments (McCulloch, 2018).  Fraser & D’Amico (2018) 
report that DR causes the most impaired vision and is the principal cause of blindness 
worldwide.  Retinopathy affects 63% of all diabetics and increases the risk of blindness 25 times 
greater than non-diabetics (Jimenez-Baez, Marquez-Gonzalez, Barcenas-Contreras, Morales-
Montoya & Espinosa-Garcia, 2015).  Regular screenings and early treatment are imperative to 
preventing progression of DR into blindness in this population.  Prevention through good 
glycemic control is but one avenue of prevention, although this is no guarantee that DR will not 
develop and certainly does not preclude one from recommended screenings (Fraser & D’Amico, 
2018).  Prompt treatment is imperative for existing disease to preserve vision (Fraser & 
D’Amico, 2018).   
Unfortunately, the longer a person is diabetic, the higher the incidence of DR (Fraser & 
D’Amico, 2018).  A meta-analysis of 35 studies conducted worldwide from 1980-2008 revealed 
DR exists in 35.4% of diabetic patients globally, and that proliferative DR exists in 7.5% of the 
global diabetic population (Solomon, et al., 2017).  In developed countries, the leading cause of 
new onset blindness in adults aged 20-74 is DR (Solomon, et al., 2017). 
Up to one-fifth of patients first diagnosed with T2DM already have signs of DR, and 
should, obtain their first screening at the time of diagnosis (Solomon et al, 2017).  Thereafter, 
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annual exams are encouraged.  However, for the sake of cost-effectiveness, bi-annual exams may 
be encouraged for the well-controlled T2DM who has had a normal retinal examination 
(Solomon, et al., 2017).  
Ninety eight percent of visual loss is preventable with regular follow up, early detection 
and treatment.  Since proliferative DR and macular edema are painless, leaving the patient often-
times asymptomatic, it is imperative to provide this population with regular examinations and 
subsequent treatment.  This only re-iterates the importance of Primary Care Providers referring 
these patients for examination and treatment.  Solomon et al. (2017) stress the importance of 
documenting these examinations in the patient’s electronic health record in the Primary Care 
Provider’s office.  This necessitates closed loop communication between the Primary Care 
Provider and the Ophthalmologist performing the DR screenings and or treatments. 
In October 2017 a formal referral protocol was implemented at Norton Community 
Medical Associates (NCMA) in Mount Washington, KY to increase retinopathy screening and 
documentation rates among patients with T2DM (Campbell, 2017).  A referral form was 
developed to fax to the optometrist or ophthalmologist with a request to fax the completed form 
back to the primary care provider upon completion of the patient’s visit.  The completed form 
included retinal examination findings and recommendations for follow-up.  A 4-week follow-up 
evaluation showed no statistically significant difference in referral and documentation rates from 
pre- to post-protocol implementation.  However, providers in the clinic found the process helpful 






The overall objective of this project was to evaluate the referral process implemented at 
NCMA Mount Washington, KY to increase DR screening and documentation rates among 
patients diagnosed with T2DM.  More specifically, this project focused on the following 
objectives: 
1.  Compare the rate of referrals for DR screening from pre-implementation to post-
implementation years of the referral protocol. 
2. Compare documentation rates of DR screening exams from years pre-implementation to 
post-implementation of the referral protocol. 
Methods 
Design.  A retrospective chart review was used to evaluate the referral process for DR 
screening and formal documentation at NCMA Mount Washington, KY.   
Sample.  Inclusion criteria were ages 18 to 70 years old with a diagnosis of T2DM, 
(ICD-10 codes E-11 to E-11.9) who were seen at the NCMA Mount Washington, KY Clinic.  
Exclusion criteria were ages younger than 18 and older than 70 years old and without a diagnosis 
of diabetes.  There were no exclusions for sex/gender or racial/ethnic groups.  For the pre-
implementation phase a random sample of the electronic health records of 100 patients who met 
the inclusion criteria and were seen between January 1, 2017 and May 1, 2017 at the NCMA 
Mount Washington Clinic were reviewed.  For the post-implementation phase a random sample 
of the electronic health records of 100 patients who met the inclusion criteria and were seen 




Informed Consent. Informed consent was waived for this project since it was a 
retrospective chart review that presented no more than minimal risk to the participants.  
Procedure.  The Norton Healthcare Information Technology Department was provided 
with inclusion and exclusion criteria.  The department used the inclusion and exclusion criteria to 
randomly select 100 medical records from the pre-implementation phase and 100 medical 
records from the post-implementation phase.  These charts were reviewed for formal referral 
documentation for DR screenings along with formal documentation of the result of screenings.  
Ninety-one charts were included in the pre-implementation review, and 96 charts were included 
in the post-implementation review.  Nine patient records in the pre-implementation period and 4 
patient records in the post implementation period were excluded either by death of the patient or 
age criteria.  The medical record numbers of each patient were given a unique study ID number 
and placed in a crosswalk table.  The data contained in the crosswalk table and the spreadsheet 
were stored in separate files on the principal investigator’s identity-authenticated secure H-drive, 
in a firewall-protected electronic research folder at Norton Healthcare (NHC) that is only 
accessible to the principal investigator, NHC Information Services representative(s) and NHC 
UK College of Nursing Academic Partnership network administrators trained to establish file 
folder access.  Demographics collected for this study were age, sex, race, and HgbA1C. 
Data Analysis.  Data analysis was accomplished using SPSS software and the crosswalk 
table.  The mean age, and HgbA1C levels were calculated.  The race and sex of the individuals 
was tallied.  A chi-square test was used to determine the rates of referral and formal 





 Sample Characteristics  The demographics of the randomly selected charts included in 
the pre-implementation phase are displayed in Table 1.  The majority of patients pre- and post-
implementation were Caucasian.  The difference between male and female pre- and post-
implementation were similar, with 92 male and 95 females included.  The mean age of patients 
randomly selected for this study were 54.6 years-old pre-implementation and 55.2 years-old 
post-implementation.  The average HbgA1C level was 7.6 pre-implementation and 7.9 post-
implementation. 
Documentation of Screening and Referrals.  The number of patients receiving formal 
referral for DR screening were 19 pre- (2017) and 26 post- (2018) implementation (p=.321).  
While some improvement was shown, it was not statistically significant.  The number of patients 
having formal documentation of screening were 16 pre-implementation (2017), and six post-
implementation (2018) (p=.016).  This is statistically significant; however, in the wrong direction 
from what was hoped (see Table 2).  This also brings to light the possible lack of closed loop 
communication between primary care providers and ophthalmologists providing DR screenings.   
Further, it should be noted that providers stand to gain anywhere from $37.50 to $75.00 
per formally documented retinopathy screening (Blue Cross and Blue Shield, 2017; Centers for 
Medicare and Medicaid Services (2015).  This study alone shows only a small portion of the 
diabetic community in this one practice.  Of the 187 patients who should have received 
screening, only 32 (33.4%) total in the pre- and post-implementation phases generated revenue 
back to the provider.  More importantly, these 32 patients received benefit of screening and 




It appears the providers in the study clinic are discussing the need for DR screening in 
this population as evidenced by Norton Healthcare’s Best Practice Screening Reminder for the 
providers, as most indicated DR was discussed with the patient; however, the use of formal 
referral and formal documentation of examination results are sporadic.  This data was not the 
focus of this study and was therefore, not collected, although it was a part of the review process.  
Some formal documentation is present in some patient’s EHR, but documentation is far from 
complete. 
 It is possible that there are those patients who seek eyecare from outside the Norton 
Healthcare system or whose insurance does not require referral.  It is also possible there are those 
that do not seek out the screening, despite being told the necessity by providers.  Adil, Siddiqui, 
Waghdhare, Bhargava, & Jha (2017) report that many of the respondents in their study did not 
receive DR screening and denied knowledge of the importance in relation to their eyesight.  
Likewise, Pasqual et al., (2015) report the results of their study found that there is a high non-
compliance rate of DR screening among the T2DM population.   
 Limitations.  This study was short-in-duration and did not capture a full year of data.  
Perhaps a longer study period would capture more of this population receiving formal referral 
and formal documentation for DR screenings.  Since these patients are screened every 3 months 
by the provider when they are considered uncontrolled diabetics, and every 6 months when they 
are considered controlled diabetics, it is possible that a lot of these individuals did not fall within 
the study period. 
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 Implications for Clinical Practice.  With the American Diabetes Association (ADA) 
guidelines suggesting regular screening for this population, it is imperative that providers strive 
to ensure these patients receive the care needed to prevent blindness.  Providers coordinate care 
for these patients on a regular basis and need to ensure the patient understands the importance of 
regular eye examinations.  In addition to formal referral for ophthalmologic retinopathy 
screening, perhaps the appointment could be confirmed while the patient is still in the office to 
ensure the patient is aware of the appointment, and is amenable to it, as well as stressing the 
importance of following through with the appointment.  In addition, the patient could return a 
formal copy of the retinopathy screening for inclusion in their medical records. 
 Implications for Further Study.  Barriers to receiving an ophthalmological screening in 
the T2DM population should be explored.  The barriers foreseen are transportation, time, and the 
difficulties of attending so many appointments in these patients.  While providers cannot make a 
patient obtain a DR screening, they certainly can assist in addressing any barriers that may exist.  
Perhaps an automated system to follow up on receipt of formal documentation could be 
implemented within the EPIC system to ensure reminders to both the provider and the 
ophthalmologist are generated, increasing the likelihood of receipt of formal documentation. 
Conclusion 
 While providers are aware of the necessity to screen the T2DM population regularly to 
provide prompt treatment preventing blindness, there still appears to be a deficit among this 
sample in receiving screenings and having formal documentation added to their medical records.  
Whatever the issue, it behooves the primary care provider to encourage patients to obtain 
screenings to prevent blindness and assist in any way possible to alleviate barriers to care. 
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Table 1. Demographics of Study Population 
 





Age, mean (SD) 54.6 (9.6) 55.2 (8.6) 1.008 
HGA1C 7.6 7.9 .874 
Gender, no. (%) 
   Male 








Race, n (%) 
   Caucasian 
   American Indian 
    Asian 
   African American 
   Other 






















Table 2. Diabetic Retinopathy Referrals and Formal Documentation Rates 
 





Referral to ophthalmology 
   Yes 









Documentation of screening 
   Yes 
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